Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AML

52

Pipeline Programs↗

58

Active Trials↗

51

Companies Involved↗

AML is a moderately active landscape with 52 programs across 51 companies. The most active players are Sanofi, CERo Therapeutics Holdings, Inc., Shengke Pharmaceuticals (Jiangsu) Limited, China. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

46/100

Mech. Concentration

13/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Sanofi

1 program

CERo Therapeutics Holdings, Inc.

1 program

Shengke Pharmaceuticals (Jiangsu) Limited, China

1 program

Pipeline

Programs by Phase

Preclinical7

Liposomal Mitoxantrone

Institute of Hematology & Blood Diseases Hospital, China

Daunorubicin+cytarabine

Institute of Hematology & Blood Diseases Hospital, China

Ivosidenib,venetoclax,gilteritinib,selinexor

Institute of Hematology & Blood Diseases Hospital, China

Closed Loop With Pramlintide

University of Virginia

Open Loop With Pramlintide

University of Virginia

Phase 124

ETH-155008

Shengke Pharmaceuticals Pty Ltd

Soc

Pfizer

Ziftomenib

Kura Oncology, Inc.

Gilteritinib

Astellas

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 215

Hyperbaric Oxygen

Intermountain Health Care, Inc.

Lisaftoclax

Ascentage Pharma Group Inc.

Ivosidenib

Servier

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Revumenib

Syndax Pharmaceuticals

Phase 36

Daunorubicin

Hikma Pharmaceuticals LLC

Idarubicin

Pfizer

Cyclophosphamide

Baxter Healthcare Corporation

Homoharringtonine

Ascentage Pharma Group Inc.

G-CSF

Arog Pharmaceuticals, Inc.

Approved

No programs

Analysis

Modality Breakdown

89%

Small molecule

40 of 45 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 98% of 52 pipeline programs.

Analysis

Trial Status

173

clinical trials

Completed64 · 37%

Recruiting37 · 21%

Terminated22 · 13%

Unknown status18 · 10%

Not yet recruiting13 · 8%

Withdrawn8 · 5%

Other11 · 6%

Clinical Trials

Trial Activity

173 trials

Bu/Cy/Flu/ATG Versus Bu/Cy/ATG Conditioning Regimen in Elderly AML Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation: a Prospective, Randomized, Controlled Study

Recruiting·PPeking University People's Hospital·Preclinical·NCT06946602·307 enrolled

An Open-Label, Multicenter, First-in-Human Trial of GEN3018 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Recruiting· Genmab logo

Genmab·Phase 1·NCT07384715·78 enrolled

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

Recruiting·CCERo Therapeutics Holdings, Inc.·Phase 1·NCT06834282·18 enrolled

A Prospective, Single-arm, Open-label, Multicenter Phase II Trial Evaluating the Efficacy and Safety of Ivosidenib Maintenance Therapy After Allogeneic Stem Cell Transplantation (alloSCT) in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasia (MD) Carrying an IDH1 Mutation

Recruiting·TTechnische Universität Dresden·Phase 2·NCT06717958·76 enrolled

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Recruiting·KKura Oncology, Inc.·Phase 1·NCT06001788·171 enrolled

A Multicenter, Randomized, Controlled Clinical Trial of Intermediate-dose HAD Regimen for CEBPA Double-mutated Acute Myeloid Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT06529250·148 enrolled

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT06265545·458 enrolled

A Single-Arm, Open-Label Study of Venetoclax, Azacitidine, and Liposomal Mitoxantrone (VAM) as Induction Therapy in Newly-diagnosed Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07490288·27 enrolled

Anthracycline-based Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1: a Prospective, Randomized, Controlled Phase III Clinical Trial

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT06744504·284 enrolled

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Recruiting·TTScan Therapeutics, Inc.·Phase 3·NCT07702578·310 enrolled

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

Recruiting·TTScan Therapeutics, Inc.·Phase 1·NCT05473910·310 enrolled

A Phase 1 Study of Rebecsinib, a Spliceosome Modulator That Inhibits ADAR1, in Patients With Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis

Recruiting·AAspera Biomedicines, Inc.·Phase 1·NCT07250646·28 enrolled

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06220162·32 enrolled

Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling

Recruiting·—·Phase 2·NCT05431257·117 enrolled

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

Recruiting·VVirginia Commonwealth University·Phase 1·NCT07130695·15 enrolled

Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)